PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:消息已过时
北京时间·🕒 发布 07:53:00·⟳ 抓取 07:54:30 +1m30s·⚡ 决策 09-01 07:55:16 +46s·56.8 天前
Rosen律所发布Disc Medicine证券集体诉讼调查广告，基于2026年2月已发生的FDA CRL事件
本条信号为Rosen律所的证券集体诉讼调查招募广告（Attorney Advertising），底层催化事件是2026年2月13日FDA对Disc Medicine bitopertin NDA发出完整回复函（CRL），距今已超6个月，股价当日已跌22%完成重定价。新闻稿不含任何新增事实、新监管动作或新信息，属于典型的律所营销通稿，无交易价值。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigat…
不做 Disc Medicine（IRON.US）
本条信号为律所集体诉讼调查招募广告（Attorney Advertising），底层FDA CRL事件发生于2026年2月13日已超6个月，股价当日跌22%已充分定价。新闻稿不含任何新增事实或监管进展，不构成可交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Rosen律所发布针对Disc Medicine的集体诉讼调查广告，底层事件为2026年2月13日FDA对bitopertin发出CRL导致股价跌22%。该事件已过去6个月以上，市场早已完成定价。本条新闻稿本身是律所营销材料，不含任何关于公司业务、监管或财务的新增信息，无法构成任何方向的交易催化。
🔎 新鲜度:最早出现 2026-02-13 · 扩散 high · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:无先例进入权衡，因事件本身不构成可交易催化
方向:不适用
涨幅量级:不适用
形态:不适用
原文全文
展开原文 · 2,851 字
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine's stock price fell 22% on February 13, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.
On this news, Disc Medicine's stock price fell 22% on February 13, 2026.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。